Gain Therapeutics (NASDAQ:GANX – Get Free Report) and Century Therapeutics (NASDAQ:IPSC – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.
Profitability
This table compares Gain Therapeutics and Century Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gain Therapeutics | N/A | -161.59% | -118.36% |
| Century Therapeutics | N/A | -49.51% | -38.09% |
Earnings & Valuation
This table compares Gain Therapeutics and Century Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gain Therapeutics | $50,000.00 | 1,619.04 | -$20.16 million | ($0.50) | -3.71 |
| Century Therapeutics | $109.16 million | 3.54 | -$9.58 million | ($0.93) | -2.30 |
Century Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Gain Therapeutics and Century Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gain Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Century Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
Gain Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 304.31%. Century Therapeutics has a consensus price target of $4.75, indicating a potential upside of 122.48%. Given Gain Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Century Therapeutics.
Institutional & Insider Ownership
12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 2.4% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Gain Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.
Summary
Century Therapeutics beats Gain Therapeutics on 7 of the 13 factors compared between the two stocks.
About Gain Therapeutics
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
About Century Therapeutics
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
